The European Medicines Agency (EMA) has started a review of Lemtrada (alemtuzumab) following reports of side effects affecting the heart, blood vessels, liver and immune system. These side effects are rare but potentially serious.
As a temporary measure while the review is being carried out, the EMA has advised that Lemtrada should only be started in people with relapsing remitting MS that continues to be very active despite taking at least two disease modifying drugs (DMDs) or where other DMDs cannot be taken.
If you have already started Lemtrada and are due to receive further infusions, you should continue with treatment. Anyone who has been treated with Lemtrada should continue to have monthly blood and urine tests for four years after the last treatment course.
If you have concerns, you should talk to your neurologist or MS nurse.
MS Trust launches 'Move it For MS' exercise campaign for MS Awareness Week
25 April 2019
This MS Awareness Week, we are calling on people with MS to pop on their pumps and introduce a little activity into their daily routine. Staying active doesn’t need to mean running marathons or going to the gym, it’s about doing it at your own level, at your own pace. Doing it YOUR way.
Don’t judge a book by its cover – Becky’s books help the MS Trust
24 April 2019
Our supporter Becky is raising money for the MS Trust with the sale of her beautiful handmade notebooks.
How fundraising for the MS Trust helps me to help my daughter
12 April 2019
Nick is taking part in the Great North Run for the third time in September and this year his daughter Amie will be joining him on Team MS Trust for her first half marathon. Here, Nick and Amie tell us about the inspiration behind their fundraising.